Product nameAnti-SMC1A antibody [C2M]
See all SMC1A primary antibodies
DescriptionMouse monoclonal [C2M] to SMC1A
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Recombinant fragment corresponding to Human SMC1A aa 402-894.
- HeLa cells.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.08% Sodium azide
Concentration information loading...
PurityProtein A/G purified
Our Abpromise guarantee covers the use of ab16147 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Several customers have reported the antibody not working well in IHC. We have also had reports that this antibody does not work in ICC/IF on HeLa cells.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionInvolved in chromosome cohesion during cell cycle and in DNA repair. Central component of cohesin complex. The cohesin complex is required for the cohesion of sister chromatids after DNA replication. The cohesin complex apparently forms a large proteinaceous ring within which sister chromatids can be trapped. At anaphase, the complex is cleaved and dissociates from chromatin, allowing sister chromatids to segregate. The cohesin complex may also play a role in spindle pole assembly during mitosis. Involved in DNA repair via its interaction with BRCA1 and its related phosphorylation by ATM, or via its phosphorylation by ATR. Works as a downstream effector both in the ATM/NBS1 branch and in the ATR/MSH2 branch of S-phase checkpoint.
Involvement in diseaseDefects in SMC1A are the cause of Cornelia de Lange syndrome type 2 (CDLS2) [MIM:300590]; also known as Cornelia de Lange syndrome X-linked. CDLS is a clinically heterogeneous developmental disorder associated with malformations affecting multiple systems. CDLS is characterized by facial dysmorphisms, abnormal hands and feet, growth delay, cognitive retardation and various other malformations including gastroesophageal dysfunction and cardiac, ophthalmologic and genitourinary anomalies.
Sequence similaritiesBelongs to the SMC family. SMC1 subfamily.
DomainThe flexible hinge domain, which separates the large intramolecular coiled coil regions, allows the heterotypic interaction with the corresponding domain of SMC3, forming a V-shaped heterodimer. The two heads of the heterodimer are then connected by different ends of the cleavable RAD21 protein, forming a ring structure.
modificationsPhosphorylated by ATM upon ionizing radiation in a NBS1-dependent manner. Phosphorylated by ATR upon DNA methylation in a MSH2/MSH6-dependent manner. Phosphorylation of Ser-957 and Ser-966 activates it and is required for S-phase checkpoint activation.
Cellular localizationNucleus. Chromosome. Chromosome > centromere > kinetochore. Associates with chromatin. Before prophase it is scattered along chromosome arms. During prophase, most of cohesin complexes dissociate from chromatin probably because of phosphorylation by PLK, except at centromeres, where cohesin complexes remain. At anaphase, the RAD21 subunit of the cohesin complex is cleaved, leading to the dissociation of the complex from chromosomes, allowing chromosome separation. In germ cells, cohesin complex dissociates from chromatin at prophase I, and may be replaced by a meiosis-specific cohesin complex. The phosphorylated form on Ser-957 and Ser-966 associates with chromatin during G1/S/G2 phases but not during M phase, suggesting that phosphorylation does not regulate cohesin function. Integral component of the functional centromere-kinetochore complex at the kinetochore region during mitosis.
- Information by UniProt
- Chromosome segregation protein SmcB antibody
- DXS423E antibody
- KIAA0178 antibody
All lanes : Anti-SMC1A antibody [C2M] (ab16147) at 1/1000 dilution
Lane 1 : Human BT-20 (breast cancer cell line) - whole cell lysate
Lane 2 : Human BT-474 (breast cancer cell line) - whole cell lysate
Lane 3 : Human HBL-100 (breast cancer cell line) - whole cell lysate
Lane 4 : Human HCC-1937 (breast cancer cell line) - whole cell lysate
Lane 5 : Human HME-1 (breast cancer cell line) - whole cell lysate
Lane 6 : Human Hs-578T (breast cancer cell line) - whole cell lysate
Lane 7 : Human MCF-10A (breast cancer cell line) - whole cell lysate
Lane 8 : Human MDA-MB 157(breast cancer cell line) - whole cell lysate
Lane 9 : Human MDA-MB 231 (breast cancer cell line) - whole cell lysate
Lane 10 : Human MDA-MB 436(breast cancer cell line) - whole cell lysate
Lane 11 : Human MDA-MB 453 (breast cancer cell line) - whole cell lysate
Lane 12 : Human MDA-MB 549 (breast cancer cell line) - whole cell lysate
Lane 13 : Human T47D (breast cancer cell line) - whole cell lysate
Lysates/proteins at 50 µg per lane.
All lanes : HRP conjugated rabbit anti-mouse at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 143 kDa
Observed band size: 150 kDa why is the actual band size different from the predicted?
Exposure time: 6 minutes
ab16147 has not yet been referenced specifically in any publications.